Edition:
United States

Tocagen Inc (TOCA.OQ)

TOCA.OQ on NASDAQ Stock Exchange Global Select Market

10.41USD
20 Apr 2018
Change (% chg)

$-0.07 (-0.67%)
Prev Close
$10.48
Open
$10.39
Day's High
$10.68
Day's Low
$10.22
Volume
19,505
Avg. Vol
56,815
52-wk High
$17.75
52-wk Low
$8.64

Chart for

About

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to... (more)

Overall

Beta: --
Market Cap(Mil.): $207.28
Shares Outstanding(Mil.): 19.91
Dividend: --
Yield (%): --

Financials

  TOCA.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -2.09 -- --
ROI: -81.35 -0.74 13.19
ROE: -- -2.80 15.00

BRIEF-Tocagen And ApolloBio Enter License Agreement To Develop Toca 511 & Toca FC In Greater China

* TOCAGEN AND APOLLOBIO ENTER LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE TOCA 511 & TOCA FC IN THE GREATER CHINA REGION

Apr 19 2018

BRIEF-Tocagen Q4 Loss Per Share $0.55

* TOCAGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND BUSINESS RESULTS

Mar 08 2018

BRIEF-Tocagen Receives EMA Orphan Medicinal Product Designation For Toca 511 & Toca FC For Glioma Treatment

* TOCAGEN RECEIVES EUROPEAN MEDICINES AGENCY ORPHAN MEDICINAL PRODUCT DESIGNATION FOR TOCA 511 & TOCA FC FOR THE TREATMENT OF GLIOMA Source text for Eikon: Further company coverage:

Mar 07 2018

BRIEF-Tocagen Estimates Cash, Cash Equivalents And Marketable Securities About $89.0 Million As Of Dec 31, 2017

* TOCAGEN SAYS ESTIMATE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE ABOUT $89.0 MILLION AS OF DEC 31, 2017 - SEC FILING

Jan 08 2018

BRIEF-Tocagen Q3 loss per share $0.50

* Tocagen reports third quarter 2017 financial and business results

Nov 08 2017

BRIEF-Tocagen to accelerate Toca 511 & Toca FC development into Phase 3 trial

* Tocagen to accelerate Toca 511 & Toca FC development into pivotal Phase 3 trial Source text for Eikon: Further company coverage:

Oct 26 2017

Competitors

Earnings vs. Estimates